Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 526

1.

Five-year experience with type 1 and type 2 reactions in Hansen disease at a US travel clinic.

Jacob JT, Kozarsky P, Dismukes R, Bynoe V, Margoles L, Leonard M, Tellez I, Franco-Paredes C.

Am J Trop Med Hyg. 2008 Sep;79(3):452-4.

PMID:
18784242
[PubMed - indexed for MEDLINE]
Free Article
2.

Nerve function impairment in leprosy at diagnosis and at completion of MDT: a retrospective cohort study of 786 patients in Bangladesh.

Richardus JH, Finlay KM, Croft RP, Smith WC.

Lepr Rev. 1996 Dec;67(4):297-305.

PMID:
9033200
[PubMed - indexed for MEDLINE]
3.

Incidence of acute nerve function impairment and reactions in leprosy: a prospective cohort analysis after 5 years of follow-up.

Richardus JH, Nicholls PG, Croft RP, Withington SG, Smith WC.

Int J Epidemiol. 2004 Apr;33(2):337-43.

PMID:
15082636
[PubMed - indexed for MEDLINE]
Free Article
4.

Reactions following completion of 1 and 2 year multidrug therapy (MDT).

Balagon MV, Gelber RH, Abalos RM, Cellona RV.

Am J Trop Med Hyg. 2010 Sep;83(3):637-44. doi: 10.4269/ajtmh.2010.09-0586.

PMID:
20810832
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.

Cellona RV, Balagon MF, dela Cruz EC, Burgos JA, Abalos RM, Walsh GP, Topolski R, Gelber RH, Walsh DS.

Int J Lepr Other Mycobact Dis. 2003 Dec;71(4):308-19.

PMID:
14763888
[PubMed - indexed for MEDLINE]
6.

Epidemiological characteristics of leprosy reactions: 15 years experience from north India.

Kumar B, Dogra S, Kaur I.

Int J Lepr Other Mycobact Dis. 2004 Jun;72(2):125-33.

PMID:
15301592
[PubMed - indexed for MEDLINE]
7.

Epidemiologic characteristics of leprosy reactions.

Scollard DM, Smith T, Bhoopat L, Theetranont C, Rangdaeng S, Morens DM.

Int J Lepr Other Mycobact Dis. 1994 Dec;62(4):559-67.

PMID:
7868954
[PubMed - indexed for MEDLINE]
8.

Clinico-epidemiological trends of leprosy in Himachal Pradesh: a five year study.

Jindal N, Shanker V, Tegta GR, Gupta M, Verma GK.

Indian J Lepr. 2009 Oct-Dec;81(4):173-9.

PMID:
20704072
[PubMed - indexed for MEDLINE]
9.

The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. I. Overview of the study.

Schreuder PA.

Int J Lepr Other Mycobact Dis. 1998 Jun;66(2):149-58. Erratum in: Int J Lepr Other Mycobact Dis 1998 Dec;66(4):following 609.

PMID:
9728447
[PubMed - indexed for MEDLINE]
10.

Relapses after fixed duration multiple drug therapy: the AMFES cohort.

Gebre S, Saunderson P, Byass P.

Lepr Rev. 2000 Sep;71(3):325-31.

PMID:
11105491
[PubMed - indexed for MEDLINE]
11.
12.

Impairments in multibacillary leprosy; a study from Brazil.

Pimentel MI, Nery JA, Borges E, Gonçalves RR, Sarno EN.

Lepr Rev. 2004 Jun;75(2):143-52.

PMID:
15282965
[PubMed - indexed for MEDLINE]
13.

Hepatic and haematological adverse reactions associated with the use of multidrug therapy in leprosy--a five year retrospective study.

Kaluarachchi SI, Fernandopulle BM, Gunawardane BP.

Indian J Lepr. 2001 Apr-Jun;73(2):121-9.

PMID:
11579648
[PubMed - indexed for MEDLINE]
14.

New lesions after MDT in PB and MB leprosy: a report of 28 cases.

Kar HK, Sharma P.

Indian J Lepr. 2008 Jul-Sep;80(3):247-55.

PMID:
19432355
[PubMed - indexed for MEDLINE]
15.

Clinical analysis of multibacillary leprosy patients after 1-year fixed World Health Organization recommended multidrug therapy at Yangon General Hospital, Myanmar.

Kyaw K, Tsoh TM, Swe SY, Nagaoka Y, Takezaki S, Suzuki K, Ishii N.

J Dermatol. 2008 May;35(5):264-9. doi: 10.1111/j.1346-8138.2008.00464.x.

PMID:
18477225
[PubMed - indexed for MEDLINE]
16.

Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.

Kaur I, Dogra S, Kumar B, Radotra BD.

Int J Lepr Other Mycobact Dis. 2002 Sep;70(3):174-81.

PMID:
12483965
[PubMed - indexed for MEDLINE]
17.

The ALERT MDT Field Evaluation Study (AMFES): a descriptive study of leprosy in Ethiopia. Patients, methods and baseline characteristics.

Saunderson P, Gebre S, Desta K, Byass P.

Lepr Rev. 2000 Sep;71(3):273-84.

PMID:
11105487
[PubMed - indexed for MEDLINE]
18.
19.

Gender differences in epidemiological factors associated with treatment completion status of leprosy patients in the most hyperendemic district of Nepal.

Kumar RB, Singhasivanon P, Sherchand JB, Mahaisavariya P, Kaewkungwal J, Peerapakorn S, Mahotarn K.

Southeast Asian J Trop Med Public Health. 2004 Jun;35(2):334-9.

PMID:
15691132
[PubMed - indexed for MEDLINE]
20.

Relapse in MB leprosy patients treated with 24 months of MDT in south west China: a short report.

Shen J, Liu M, Zhang J, Su W, Ding G.

Lepr Rev. 2006 Sep;77(3):219-24.

PMID:
17172002
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk